XML 51 R41.htm IDEA: XBRL DOCUMENT v3.20.2
RELATED PARTY TRANSACTIONS (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 6 Months Ended 9 Months Ended 10 Months Ended 15 Months Ended
Jun. 28, 2019
Jun. 27, 2019
Oct. 09, 2015
Oct. 31, 2020
Jul. 31, 2017
Mar. 31, 2017
Jun. 27, 2019
Sep. 30, 2020
Sep. 30, 2019
Apr. 30, 2020
Jul. 31, 2021
Dec. 31, 2019
Related Party Transaction [Line Items]                        
Aggregate principal of promissory notes and accrued interest               $ 6,000        
Number Of Common Stock Need To Hold To Designate As Director         600,000              
Proceeds from License Fees Received     $ 5,000                  
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.01                      
Warrant to purchase shares of common stock 10,000,000                      
Class Of Warrants Or Rights, Expiry Period         5 years              
Royalty Receivable               6       $ 82
Subsequent event | AD Pharma Agreement                        
Related Party Transaction [Line Items]                        
Proceeds from License Fees Received       $ 200                
MainPointe (Nexafed)                        
Related Party Transaction [Line Items]                        
Proceeds from License Fees Received           $ 2,500            
Asset Transferred, License Agreement           $ 309            
Licensing Agreement, Royalty Percentage           7.50%            
MainPointe (Nexafed) | Royalty                        
Related Party Transaction [Line Items]                        
Royalty revenues               9 $ 16      
Investor                        
Related Party Transaction [Line Items]                        
Warrant to purchase shares of common stock         1,782,531              
Investor | Private Placement                        
Related Party Transaction [Line Items]                        
Sale of Stock, Consideration Received on Transaction         $ 4,000              
Sale of Stock, Number of Shares Issued in Transaction         8,912,655              
Sale of Stock, Price Per Share         $ 0.4488              
Class of Warrant or Right, Exercise Price of Warrants or Rights         $ 0.528              
Sale Of Stock, Issue Price Description         85%              
Warrants Not Settleable in Cash, Fair Value Disclosure               495        
Proceeds from Issuance of Warrants               $ 4,000        
Warrant to purchase shares of common stock         1,782,532              
Schutte                        
Related Party Transaction [Line Items]                        
Aggregate principal of promissory notes and accrued interest $ 6,000                      
Fixed interest rate 7.50%                      
Share Price $ 0.16                      
Debt Conversion, Converted Instrument, Warrants or Options Issued 10,000,000                      
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.01                      
Debt Conversion, Converted Instrument, Shares Issued 37,500,000                      
Proceeds from Issuance of Long-term Debt $ 725 $ 650         $ 650          
Schutte | AD Pharma Agreement                        
Related Party Transaction [Line Items]                        
Aggregate principal of promissory notes and accrued interest $ 6,000                      
Debt Conversion, Converted Instrument, Warrants or Options Issued 10,000,000                      
Abuse Deterrent Pharma, LLC                        
Related Party Transaction [Line Items]                        
Proceeds from License Fees Received                   $ 350    
Abuse Deterrent Pharma, LLC | AD Pharma Agreement                        
Related Party Transaction [Line Items]                        
Proceeds from License Fees Received $ 350                 $ 200    
Abuse Deterrent Pharma, LLC | Subsequent event | AD Pharma Agreement                        
Related Party Transaction [Line Items]                        
Proceeds from License Fees Received                     $ 200  
Abuse Deterrent Pharma, LLC | MainPointe (Nexafed)                        
Related Party Transaction [Line Items]                        
Option product exercise price waived if the exercise of the option occured by five years $ 500                      
Period to waive option product exercise price 5 years